Navigation Links
Pregabalin Proves Durable Pain Relief Option for Fibromyalgia

Pregabalin, typically used to treat nerve pain or seizures, appears to offer extended pain relief for those with fibromyalgia, according to research presented this week at// the American College of Rheumatology Annual Scientific Meeting in Washington, DC.

Fibromyalgia is an often misunderstood syndrome that causes widespread chronic muscle pain and tenderness in 2 percent of the U.S. population, most commonly women. In addition to pain, fibromyalgia is often associated with fatigue, sleep disturbances and memory problems. Unfortunately, to date, no FDA-approved treatment has been available for this syndrome.

Researchers enrolled 1,051 participants in a six-week program of 300, 450 or 600 mg daily doses of pregabalin to optimize pain control and medication tolerance. On average, the population was 93% female, 88% white, had endured fibromyalgia for over seven years and measured their pain severity as 78 on a 100 point scale.

At the end of the 6-week program, 663 participants (63%) cited over 50% reduction in pain, and being “much” or “very much improved.” Of these, 566 were randomized into a 26-week double-blind study to receive either pregabalin at the optimal dosage established during the 6 weeks prior or placebo. The primary goal of this six-month study, one of the longest control studies conducted to date, was to determine how long their therapeutic responses lasted.

One-fourth of placebo-treated patients saw worsening by day 7 as compared to day 34 for those on medication. By the end of the double-blind treatment, nearly twice (61%) as many placebo patients had lost response as compared to 32% of the patients on medication. The most common side effects of pregabalin were dizziness, somnolence, sinusitis, joint pain and anxiety. One death occurred each in the placebo and treatment arms of the trial, but neither was treatment-related.

“Fibromyalgia is a common and often debilitating pain syndrome,” expl
'"/>




Page: 1 2

Related medicine news :

1. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
2. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
3. Pilot Study Proves Home Abortions ‘Safe’
4. Many Nonprescription Cough Medicines Proves Ineffective
5. Less Invasive By Pass Surgery Proves Economical In The Long Run
6. Epidural Mistakes Proves To Be Fatal Blunders
7. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
8. Drug Trial Proves Nightmare for British Indian Student
9. Naturopathic Care Proves Beneficial for TMD Pain
10. Medtronic Device Proves Effective in Parkinson’s Diseas
11. Large Community Spirometry Screening Proves Successful
Post Your Comments:
(Date:12/2/2008)...G, Mich., Dec. 2 Senior...nsurance companies gathered today to,oppose effor...ss legislation,through the lame duck session of t...f life or death for many of us in Michigan," said,...igan Disability Rights,Coalition. "A vote for thi...
(Date:12/2/2008)... Appointment of enterprise soft...celerate growth in revenue and subscribers of Yugm... Minneapolis, MN (PRWEB) December 2...rvice that lets people connect and collaborate ins...nt of Vas Bhandarkar as Chief Executive Officer. ,...
(Date:12/2/2008)...UMBUS, Ohio)Rare injuries accounted for 3.5 percen...007, according to the first study to examine rare ...es. Rare injuries include eye injuries, dental inj...and heat illness, which may result in high morbidi...ng consequences. , Football was associated with ...
(Date:12/2/2008)...T, Dec. 2 United America... owns and provides comprehensive healthcare,manag...ennessee, today,announced that its Board of Direc...horizing the Company to repurchase up to $1.0 mill... program allows for the Company,s common shares to...
Breaking Medicine News(10 mins):Health News:Opposition Continues to Grow to Blues' Legislation 2Health News:Opposition Continues to Grow to Blues' Legislation 3Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 2Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 3Health News:United American Healthcare Corporation Announces Stock Repurchase Program 2
...e. According to a recent study researchers find sm...eases the risk of having a baby with a cleft lip. ...d who were interviewed when their babies were abou...t the mother’s smoking habits before and during pr...
...the first step in the path for a treatment for hum...t time they have found a successful way to deliver... Gene therapy for muscular dystrophy has been a h...a delivery method for the whole body has been a ma...
... people infected with both HIV and hepatitis C hav...eir study, patients who are treated with a newer c...to rid their bodies of HCV than those who receive ...nt because as many as 300,000 of the estimated 1 m...
...may keep your blood pressure under control. Resear...who drank between 120 milliliters and 599 millilit...46-percent decreased risk of developing hypertensi...ople who consumed more than 600 milliliters a day ...
Other Medicine News:
(Date:12/1/2008)... ENB-0040 at Children,s Hospital, Health Sciences ...Newswire/ -- Enobia Pharma, an emerging Canadian b...utics for serious bone disorders, today announced ...ram for hypophosphatasia was dosed. Enobia is inve...B-0040 for the treatment of this rare and often cr...
(Date:12/1/2008)...cember 9 at 11:00 am ET to Discuss Phase 2 Study R...Calif., Dec. 1 Sunesis...rmaceutical company focused on the development and...oday announced new data from its studies of vorelo...ted during the 50th American Society of Hematology...
(Date:11/28/2008)...re/ -- German biotech company,Partec is expanding...ng and,AIDS patient follow-up diagnostics for dev... 2.5 million patient tests have been performed wit...low" system, supporting already,more than 1 milli...n of the,Partec innovation, the average cost of E...
(Date:11/26/2008)...ANKLIN, Mass., Nov. 26 P...ced today that it has received full approval from ...s U.S. pivotal trial to study the effectiveness of...ed therapy in the prevention of Contrast-Induced N... PLC,s request to expand their investigation from ...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for 2420 Million with New and Existing Institutional Investors 2134 1Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for 2420 Million with New and Existing Institutional Investors 2134 2Abdominal Fat Tied to High Risk for Coronary Trouble 8051 1Abdominal Fat Tied to High Risk for Coronary Trouble 8051 2Scientists seek to assess the microbial risks in the water we drink 8047 1Scientists seek to assess the microbial risks in the water we drink 8047 2Scientists seek to assess the microbial risks in the water we drink 8047 3Building blocks of life formed on Mars 1544 1Building blocks of life formed on Mars 1544 2
...east 45% additional,reduction in patients, LDL-cho...owering therapies, CARLSBAD, Calif., May 17, 2007 ...c. announced updated results from its ongoing,Phas... homozygous,familial hypercholesterolemia (HoFH), ...t the of Cardiology Annual Scientific Session,(ACC...
... Than for Asthma,Rheumatoid Arthritis and Migrain...y three out of,four ulcerative colitis (UC) suffer...rvey say not feeling well has become a normal part...ive when it comes,to their relationship with a spo...nt) and their emotional state (82 percent). , UC p...
Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 2Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 3Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 4Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 5Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 6Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 7Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 8Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 9
Used for temporary internal drainage from the ureteropelvic junction to the bladder. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; C-Flex
Used for catheter or instrument introduction. The dual knobs allow the sheath to be peeled away and removed. The maximum diameter of the catheter or instrument to be introduced should be measured to
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use.
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: